Business Wire

TX-MARY-KAY/GENDER-GAP

2.9.2022 18:01:39 CEST | Business Wire | Press release

Share
Gender Equality Cannot Wait 132 Years

Below is a statement by Julia A. Simon, Chief Legal and Chief Diversity & Inclusion Officer, Mary Kay Inc., on the release of the 2022 World Economic Forum’s Global Gender Gap Report.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220831005218/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Julia Simon, Chief Legal Officer and Chief Diversity & Inclusion Officer (Photo Credit: Mary Kay Inc.)

According to a sobering finding from the World Economic Forum’s 2022 Global Gender Gap Report, gender parity is beyond reach in our lifetime. In fact, according to the report, it will take 132 years for gender equality to become a reality and 151 years to close the economic participation and opportunity gender gap. Not a single country from the 146 examined has reached parity.

That’s the bad news.

The good news? There’s still time to change all that. The 2022 findings have shaken me, but they have not deterred me. Nor should they deter you.

Gender equality is a prerequisite not only for human development—but sustainable economic growth. A rich body of data shows that without gender parity it is impossible to reduce poverty, attain food security, address climate impacts, or ensure a more peaceful and inclusive society. Gender parity isn’t a “nice to have.” It’s also not just a perk of developed nations. It is an essential requirement for all countries to develop and prosper.

To mitigate further backsliding, the structural barriers limiting women’s labor market participation, including their re-entry and retention in the workforce following COVID-19, must be addressed. Targeted policies which support women’s talent development in the industries of the future, and which accelerate their advancement to leadership and management positions, are also needed.

The private sector has a critical role to play in addressing gender gaps in the workplace and in developing the pipeline of women for leadership positions. As a company founded by a barrier-breaking businesswoman almost 60 years ago, this is personal to Mary Kay.

In 2019, Mary Kay signed the Women’s Empowerment Principles (WEPs) and in 2021 the company became a Commitment Maker to the Generation Equality Forum Action Coalitions to accelerate progress on gender equality to advance the Sustainable Development Goals.

Mary Kay is participating in the 2022-2023 UN Global Compact Target Gender Equality accelerator programme to continue the implementation of ambitious corporate targets for women’s representation and leadership in the company and in our supply chain. Leading by example and reflecting our belief in increased women’s inclusion, Mary Kay is putting our values and commitments into action:

Women’s Representation and Leadership at Mary Kay (Data from August 2022):

  • 62% of our Global Workforce are Women
  • 50% of our Executive Team are Women
  • 53% of our Vice Presidents and above are Women
  • 57% of our Directors and above are Women
  • 59% of our Managers and above are Women
  • 70% of our Market Leaders are Women
  • 60% of our Leaders in our Top 10 Markets are Women

Gender-Responsive Procurement & Supplier Diversity at Mary Kay (U.S. only supply chain data from February 2021):

  • 66% of our Procurement Team are Women
  • 12% of our Indirect Suppliers are Women, Minority or Veteran-Owned
  • 5% of our Direct Suppliers are Women, Minority or Veteran-Owned

Our 10-year Sustainability Strategy, titled Enriching Lives Today for a Sustainable Tomorrow, pursues a holistic approach to advancing gender equality and women’s empowerment with the following key commitments to achieve by 2030:

  • Economically empower 5 million women worldwide
  • Ensure access to education for 250,000 women and girls globally
  • Provide over 10 million women worldwide with gender-based violence support services, and
  • Develop a 10-year policy agenda to address women’s rights

Inspired by our mission as an entrepreneurship development company founded by a woman for women, we are committed to advancing women’s entrepreneurship and dismantling the barriers to women’s economic empowerment. We brought this vision to the United Nations in 2019 and, together with 6 UN agencies, we incepted the Women’s Entrepreneurship Accelerator (WEA) to create an enabling ecosystem for women entrepreneurs.

The time to act is now. Sitting on the sidelines and waiting 132 years is simply not an option. The Sustainable Development Impact Meeting on “Advancing Gender Equality”, which takes place in New York this month, is an opportunity for leaders from the public and private sector to identify tools and strategies to close the gender gap. We owe it to future generations to mobilize our efforts to make the transformative changes that are so badly needed for women and girls.

ABOUT MARY KAY

One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors of domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn, or follow us on Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220831005218/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye